Dyne Therapeutics, Inc. financial data

Symbol
DYN on Nasdaq
Location
1560 Trapelo Road, Waltham, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.61K % +9.72%
Debt-to-equity 17.4 % +53.9%
Return On Equity -66.2 % -15.1%
Return On Assets -56.4 % -9.16%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 143M shares +40.3%
Common Stock, Shares, Outstanding 143M shares +40.2%
Entity Public Float 3B USD +495%
Common Stock, Value, Issued 14K USD +40%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 385M USD +48.9%
General and Administrative Expense 64.5M USD +15.1%
Operating Income (Loss) -449M USD -42.9%
Net Income (Loss) Attributable to Parent -424M USD -43.9%
Earnings Per Share, Basic -3 USD/shares -3.08%
Earnings Per Share, Diluted -3 USD/shares -3.08%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 574M USD +7.79%
Assets, Current 806M USD +9.49%
Property, Plant and Equipment, Net 24M USD +390%
Operating Lease, Right-of-Use Asset 21.8M USD -14.8%
Assets 867M USD +12.8%
Accounts Payable, Current 12.1M USD +95.9%
Employee-related Liabilities, Current 13.2M USD +16.5%
Liabilities, Current 59.8M USD +38.3%
Operating Lease, Liability, Noncurrent 16.3M USD -18.8%
Liabilities 175M USD +177%
Accumulated Other Comprehensive Income (Loss), Net of Tax 496K USD +3.77%
Retained Earnings (Accumulated Deficit) -1.28B USD -49.3%
Stockholders' Equity Attributable to Parent 692M USD -1.95%
Liabilities and Equity 867M USD +12.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -106M USD -34.8%
Net Cash Provided by (Used in) Financing Activities 141M USD -65.4%
Net Cash Provided by (Used in) Investing Activities 1.46M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 143M shares +40.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 36.8M USD -75.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 576M USD +7.78%
Deferred Tax Assets, Valuation Allowance 289M USD +98%
Deferred Tax Assets, Gross 295M USD +94.6%
Operating Lease, Liability 24M USD -12.5%
Payments to Acquire Property, Plant, and Equipment 981K USD +414%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -424M USD -44.1%
Lessee, Operating Lease, Liability, to be Paid 27.9M USD -15%
Property, Plant and Equipment, Gross 32.2M USD +182%
Operating Lease, Liability, Current 5.04M USD +4.67%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.13M USD +2.74%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.98M USD +2.77%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.87M USD -27.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.28M USD +2.74%
Deferred Tax Assets, Operating Loss Carryforwards 86.2M USD +50%
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.44M USD +2.74%
Additional Paid in Capital 1.98B USD +26.2%
Depreciation, Depletion and Amortization 1.99M USD +20.8%
Deferred Tax Assets, Net of Valuation Allowance 6.64M USD +10.4%
Share-based Payment Arrangement, Expense 45.1M USD +9.69%
Interest Expense 2.9M USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%